学术报告

当前位置: 首页  >  科学研究  >  学术报告  >  正文

In vivo CRISPR screening reveals targets to reprogram long-lived effector T cells for cancer immunotherapy 

时间:2020-01-07     浏览次数:

报告人:龙凌云 博士 美国圣裘德儿童研究医院St. Jude Children’s Research Hospital, Memphis, TN, USA)

邀请人:张佩景教授

报告时间:2020年1月15日(周三)15:00-16:00

报告地点:十大网赌靠谱平台东十一楼二楼大会议室


报告人简介:

龙凌云博士,美国圣裘德儿童研究医院St. Jude Children’s Research Hospital, Memphis, TN, USA博士后2006年本科毕业于武汉大学生命科学学院,2013年获得中科院上海生命科学研究院博士学位。2014年至今在美国圣裘德儿童研究医院迟洪波教授Chi hongbo)实验室接受博士后训练,长期从事抗病毒天然免疫、肿瘤免疫治疗等方面研究,以第一作者身份在国际著名期刊NatureImmunity发表了10余篇SCI论文

报告摘要

Adoptive cell therapy represents a new paradigm in cancer immunotherapy, but it can be limited by the poor persistence and function of transferred T cells. Here we use an in vivo pooled CRISPR–Cas9 mutagenesis screening approach to demonstrate that, by targeting REGNASE-1, CD8+ T cells are reprogrammed to long-lived effector cells with extensive accumulation, better persistence and robust effector function in tumours. REGNASE-1-deficient CD8+ T cells show markedly improved therapeutic efficacy against mouse models of melanoma and leukaemia. Our findings suggest that T cell persistence and effector function can be coordinated in tumour immunity and point to avenues for improving the efficacy of adoptive cell therapy for cancer.

欢迎老师与同学积极参加!